This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (4)  • Contact me when this article is cited  Related Content  • Related article  • Similar articles in this journal  Topic Collections  • Oncology  • Treatment Adherence  • Statistics and Research Methods  • Prognosis/ Outcomes  • Adherence  • Drug Therapy, Other  • Gastrointestinal Diseases  • Alert me on articles by topic  Social Bookmarking   What's this?

Noel S. Weiss, MD, DrPH; Thomas D. Koepsell, MD, MPH; Bruce M. Psaty, MD, MPH

Arch Intern Med. 2008;168(2):133-135.

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

The CONSORT (Consolidated Standards of Reporting Trials) guidelines,¹ now endorsed by many major medical journals (including the Archives of Internal Medicine), chiefly highlight aspects of randomized trial methods that bear on a trial's internal validity—that is, whether the trial reaches the correct conclusion regarding individuals actually enrolled. Among these features are whether assignments are truly made at random, whether the health outcomes of concern are monitored accurately in all participants, and whether a large enough number of such outcomes occur in the participants to yield statistically precise results.

The results of such trials are most directly generalizable to study-eligible patients who would have enrolled and who receive the same interventions provided in the trial setting. However, as Dhruva and Redberg illustrate in this issue of the Archives,² the demographic profile of a trial's . . . [Full Text of this Article]

NATURE OF THE TREATMENT PROTOCOL


PATIENT CHARACTERISTICS

ADHERENCE

DURATION OF TREATMENT AND FOLLOW-UP

CONCLUSIONS

AUTHOR INFORMATION


CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

RELATED ARTICLE

Variations Between Clinical Trial Participants and Medicare Beneficiaries in Evidence Used for Medicare National Coverage Decisions
Sanket S. Dhruva and Rita F. Redberg
Arch Intern Med. 2008;168(2):136-140.
ABSTRACT | FULL TEXT  

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

How to increase the value of randomised trials in COPD research
Puhan and Schunemann
Eur Respir J 2009;34:552-558.
ABSTRACT | FULL TEXT  

How to assess the external validity of therapeutic trials: a conceptual approach
Dekkers et al.
Int J Epidemiol 2009;0:dyp174v1-dyp174.
ABSTRACT | FULL TEXT  

Should we use large scale healthcare interventions without clear evidence that benefits outweigh costs and harms? No
Landefeld et al.
BMJ 2008;336:1277-1277.
FULL TEXT